Multiple myeloma is a rare and highly heterogeneous hematologic malignancy, and the clinical research certainly plays a fundamental role in the management of patients with this disease. To deal with such a complex scenario, in 2005, a group of European hematologists pull together to increase their understanding of multiple myeloma and to produce effective research projects and clinical trials. These efforts resulted in the creation of the European Myeloma Network (EMN). According to the recently updated bylaw in 2017, the network board is composed of renowned experts in the hematologic field: Pieter Sonneveld from the Netherlands (Chairman), Mario Boccadoro from Italy (Secretary), Jesus Fernando San Miguel Izquierdo from Spain (Member), Herman Cristoph Einsele from Germany (Member), Meletios Athanasios Dimopoulos from Greece (Member), and Heinz Ludwig from Austria (Member). The board is going to expand in 2019, and newer members from other countries are being included: Philippe Moreau from France (Member), Roman Hajek from Czech Republic (Member), Annette Vangsted from Denmark (Member) and Gordon Cook from the United Kingdom (Member).